Multifactorial diseases, including autoimmune juvenile idiopathic arthritis (JIA), result from a complex interplay between genetics and environment. Epigenetic mechanisms are believed to integrate such gene-environment interactions, fine-tuning gene expression, and possibly contributing to immune system dysregulation. Although anti-TNF therapy has strongly increased JIA remission rates, it is not curative and up to 80% of patients flare upon treatment withdrawal. Thus, a crucial unmet medical and scientific need is to understand the immunological mechanisms associated with remission or flare to inform clinical decisions. Here, we explored the CD4 + T-cell DNA methylome of 68 poly-articular and extended oligo-articular JIA patients, before and after anti-TNF therapy withdrawal, to identify features associated with maintenance of inactive disease. Individual CpG sites were clustered in coherent modules without a priori knowledge of their function through network analysis. The methylation level of several CpG modules, specifically those enriched in CpG sites belonging to genes that mediate T-cell activation, uniquely correlated with clinical activity. Differences in DNA methylation were already detectable at the time of therapy discontinuation, suggesting epigenetic predisposition. RNA profiling also detected differences in T-cell activation markers (including HLA-DR) but, overall, its sensitivity was lower than epigenetic profiling. Changes to the T-cell activation signature at the protein level were detectable by flow cytometry, confirming the biological relevance of the observed alterations in methylation. Our work proposes epigenetic discrimination between clinical activity states, and reveals T-cell-related biological functions tied to, and possibly predicting or causing, clinical outcome.
arthritis | epigenetics | T-cell activation | DNA methylation signature | transcriptomics J uvenile idiopathic arthritis (JIA) is the most common chronic childhood rheumatic disease and encompasses several forms, including extended oligo-and poly-articular JIA. Disease is characterized by chronic joint inflammation and synovial accumulation of activated autoreactive T cells (1) . The low concordance rate between monozygotic twins (20-40%) (2) underscores that, although there is a genetic component to this autoimmune condition, environmental triggers and stochastic events are fundamental to disease pathogenesis. Epigenetic mechanisms are believed to integrate environmental influences on gene expression, possibly affecting immune system dysregulation and autoimmune manifestations (3) . In this regard, epigenetic variation has been associated with various rheumatic diseases, including adult rheumatoid arthritis (RA) (4, 5) , lupus (6, 7) , and JIA (8) . In addition, Liu et al. (9) identified two differentially methylated regions within the major histocompatibility complex (MHC) locus between RA patients and healthy controls, and suggested that a proportion of the risk conferred by the MHC region in RA is in fact mediated by altered DNA methylation.
Currently, the most effective treatment for JIA is anti-TNF, usually in combination with the first-line therapeutic, methotrexate. Unfortunately, 50-80% patients flare upon treatment withdrawal (10), thus requiring continued immunosuppressive treatment with its associated safety risks and costs (11) . At the time of therapy withdrawal, patients who will eventually maintain inactive disease (ID) are clinically indistinguishable from those who will not. Thus, to better guide clinical decisions, it is crucial to unravel the mechanisms underlying disease remission.
Whereas most studies focus on the role of epigenetics in disease onset, we hypothesized that DNA methylation is also associated with responsiveness to therapy and subsequent maintenance of ID. We took advantage of the availability of well-characterized samples from a clinical trial that was designed to study rates and mechanisms
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of clinical relapse upon therapy withdrawal in patients who had initially achieved ID while on anti-TNF. By performing gene network analysis, we were able to identify differences in the DNA methylation of various T-cell activation genes that were specifically associated with clinical outcome. These changes were already evident at the time of therapy withdrawal and led to functional changes in the protein expression levels of molecules involved in T-cell activation. This study provides insight into the immunological mechanisms underlying disease remission and relapse, and reveals a previously unappreciated application of epigenetic analysis in distinguishing between clinical activity states in autoimmune arthritis.
Results
CpG Modules Are Associated with Clinical Activity. We measured the genome-wide DNA methylation status of circulating CD4 + T cells collected from a homogeneous cohort of JIA patients sampled at the time of anti-TNF withdrawal (T 0 ) and at the time of flare (T end ) (10) . Nonflaring control samples were collected 8 mo after anti-TNF withdrawal, and were further segregated into patients maintaining ID (12) or not (NO ID) (Dataset S1). The latter category includes patients who did not meet the criteria to be considered inactive, while not worsening to the point of being considered flares (see SI Materials and Methods for definitions). We studied CD4
+ T cells on the basis of their fundamental role in autoimmune disease pathogenesis (1, 13, 14) , opting for fluorescence-activated cell sorting of CD4 + T cells to minimize the variability resulting from the divergent epigenetic profiles of heterogeneous peripheral blood mononuclear cell (PBMC) cell subsets (9, 15) . DNA methylation was selected from several candidate epigenetic features for its relative stability (16) (17) (18) and potential for translation into clinical settings (19) .
We used weighted gene coexpression network analysis (WGCNA) (20) (21) (22) (23) (24) (25) to aggregate statistically correlated CpG sites into coherent modules. Because correlated CpG sites are likely to be biologically coregulated, focusing the analysis on modules as opposed to single CpG sites allows for reduction of both dimensionality and noise. The information carried by a CpG module is summarized by the module eigengene (i.e., the dominant across-sample profile of the CpG sites belonging to that module) (20) . We tested the module eigengene for its association with demographic and clinical variables: age, gender, time point, and clinical activity. Gender and age served as controls, as these two traits are known to correlate with DNA methylation (26) (27) (28) (29) (30) . A number of modules were indeed strongly associated with gender and age, validating our analytical strategy [false-discovery rate (FDR)-adjusted P value between 4.92e-2 and 1.99e-70] ( Fig. 1A and Datasets S2 and S3).
Only one module was weakly associated with time point (FDR-adjusted P = 4.11e-2), suggesting that minimal variation in DNA methylation occurs upon therapy discontinuation. This finding was further supported by hierarchical clustering of the top 500 most variable CpG sites (Fig. S1 ), which showed perfect cosegregation of the two time points for each patient.
Nine CpG modules correlated with clinical activity (FDRadjusted P value between 3.85e-2 and 2.29e-4), indicating that patients with distinct clinical outcomes differ in their DNA methylation profile. However, four of nine modules were more strongly associated with demographic traits rather than with clinical outcome. Therefore, we focused on the five modules that did not correlate with either gender or age (#14, #25, #26, #29, and #30, highlighted by green arrows in Fig. 1A ; see also Dataset S4) to avoid the confounding effects of demographics. Consistent with Fig. 1A , the methylation pattern of CpG sites in NO ID patients differed from ID patients and flares (Fig. 1B) .
Together, our data suggest that DNA methylation is largely unaffected by therapy discontinuation, but differs between patients who will maintain ID and those who will not.
Modules Associated with Clinical Activity Are Enriched in CpG Sites
from the MHC Locus. We performed positional and functional enrichment on the five modules associated with clinical activity, but not gender or age. Module 26 did not yield any significant enrichment and was not investigated any further. Modules 25 and 29 scored positive for positional enrichment. Both modules were enriched for CpG sites in the cytogenetic location 6p21, which encompasses the MHC locus (FDR-adjusted P = 6.19e-6 and 4.06e-3, respectively) ( Fig. 2 and Datasets S5 and S6). When we analyzed CpG modules associated with traits other than clinical outcome, we could not find such a strong enrichment in the MHC locus, demonstrating its specific association with clinical activity. Moreover, all CpG sites associated with known single nucleotide polymorphisms were omitted from our analysis, thereby excluding the possibility that the detected epipolymorphisms were merely because of genetics (i.e., high polymorphism of the HLA locus). These findings are in line with recent literature showing that not only genetic but also epigenetic variation at the MHC locus is a risk factor for rheumatoid arthritis (9), thereby providing a possible pathogenic link between juvenile and adult autoimmune arthritis. Among the CpG sites belonging to these modules and located at 6p21, several fell into classic and nonclassic MHC genes, as well as into other immunologically relevant genes, including MICA, MICB, TRIM26, TRIM29, CCHCR1, and TNXB (Datasets S5 and S6).
In conclusion, both MHC and other immunologically relevant genes in the MHC locus are differentially methylated according to clinical outcome.
CpG Modules Associated with Clinical Activity Bear a Signature of T-Cell Activation. Next, we interrogated CpG modules for their functional significance. Of the five selected modules specifically associated with clinical outcome, modules #14 and #30 showed a remarkably similar functional enrichment profile (Fig. S2A) . The reason for this similarity is that modules #14 and #30 shared most CpG sites (Fig. S2B ) because of the almost perfect anticorrelation of their eigengenes (Fig. S2C) . The degree of overlap between modules #14 and #30 was quite unique in this network, and underscores the dominance of two anticorrelated methylation patterns related to clinical activity; that is, higher (#14) or lower (#30) methylation in NO ID patients compared with ID patients and flares (Fig. 1B and Dataset S2).
Because both modules #14 and #30 carry similar information, we focused on their union in all subsequent analyses. Importantly, not only were all of the enriched Gene Ontology (GO) terms of the merged modules #14 and #30 were immunologically relevant, but they were mostly related to T-cell activation, comprising genes such as GATA3, CXCR5, CCR7, CD5, IKZF1, ADORA2A, PRDM1, and CSK (Fig. 3A and Dataset S7). Modules #14 and #30 included multiple CpG sites for many of these genes, increasing confidence in our findings (Dataset S4). In contrast, modules predominantly associated with other variables, such as age, were enriched in GO terms related to fundamental, nonimmune functions of the cell (Fig. S3) , demonstrating the specificity of the association of the T-cell activation signature with clinical outcome.
The enrichment of modules #14 and #30 in T-cell-related pathways was unparalleled, as demonstrated by an enrichment analysis for the GO term #0050863 (regulation of T-cell activation) across all modules (Fig. 3B) . Therefore, we investigated which T-cell pathways were driving this GO classification. The top enriched pathways in modules #14 and #30 were related to TCR signaling and costimulation (Fig. 3 C and D) and comprised various CD3 subunits (D, E, G, and Z), ZAP70, LCK, CD28, CTLA4, PDCD1, and IL2RB (Dataset S8).
As noted above, CpG module #14 was associated with the time point, but to a lesser extent than clinical activity (the difference in FDR-adjusted P values is two orders of magnitude) (Dataset S2). Similarly, the association between module #30 and time point was only marginally not significant (FDR-adjusted P = 1.1e-1). Accordingly, significance analysis of individual CpG sites belonging to the modules #14 and #30 revealed stronger correlation with clinical activity than with time point (Fig. S4A) . We set out to determine whether distinct functions were associated with clinical activity-correlated vs. time point-correlated CpG sites. However, because only 50 (of 257) CpG sites were more strongly associated with time point than clinical activity, no meaningful functional enrichment analysis could be performed. To bypass this limitation, we ranked the CpG sites based on the ratio between clinical activity and time-point significance, and then equally partitioned them into the top 50% (Fig. S4B , red) and bottom 50% (Fig. S4B, blue) . Although the same pathways related to T-cell activation were found enriched in both partitions (Fig. S4B) , the enrichment was much more significant for the subgroup more strongly associated with clinical activity.
In summary, epigenetic traits differ among patients with divergent clinical outcome and target genes involved in T-cell activation and T-cell receptor (TCR) signaling, suggesting that DNA methylation may actively modulate the mechanisms underlying responsiveness to therapy. In contrast, the contribution of the time point to the overall variance seems marginal.
DNA Methylation Is More Sensitive Than Gene Expression in Identifying
the Signature of T-Cell Activation. We were able to obtain sufficient high-quality RNA to investigate the transcriptional profile of 92% of the samples tested for DNA methylation (n = 63). We applied the same unbiased network analysis used for DNA methylation to whole-genome expression data, obtaining 11 modules. The number of genes per module is listed in Dataset S9. Among the identified gene modules, one (module #5) correlated with the NO ID state (FDR-adjusted P = 4.63e-2) (Fig. 4 A and B and Datasets S10 and S11).
When we investigated this module for positional enrichment, we found that the top hit (FDR-adjusted P < 0.05) was the cytogenetic location 6p21 (Fig. 4C ), in line with our DNA methylation data. The expression of many MHC class II genes was increased in NO ID patients compared with both ID and flares (Dataset S12). This result was exemplified by HLA-DR expression (Fig.  4D) . These findings are also in line with an activated phenotype of T cells and thus consistent with our results on DNA methylation. Indeed, HLA-DR is only expressed by human T cells upon stimulation (as first described in refs. 31 and 32 and exemplified in Fig.  S5) . Therefore, at least in this context, the relevance of the MHC locus for the disease seems to reside in its up-regulation on activated T cells, and is distinct from the influence of HLA polymorphism on genetic predisposition to disease.
When we analyzed the GO classification of module #5, a number of immune cell activation pathways were enriched ( Fig.  4E and Dataset S13), most of them driven by the up-regulation of MHC class II and another less-appreciated marker of T-cell activation, CD86 (33, 34) (Fig. S5) .
Although similar functions were revealed by both methylomics and transcriptomics, correlation of modules enriched for T-cell pathways with clinical activity was higher in the DNA methylation dataset (Figs. 1A and 4A) . Indeed, CpG modules #14 and #30 showed stronger enrichment than gene module #5 for both GO (Fig. S6A) and Reactome (Fig. S6B) Analyzing protein expression might offer a more functionally relevant approach than RNA expression to validate our DNA methylation data. Therefore, we measured the abundance of proteins involved in T-cell activation by flow cytometry. Residual samples were sufficient for the analysis of one or more markers from up to 55 patients (81% of the samples). Importantly, despite the smaller number of samples available, we were able to validate the association of T-cell activation with clinical outcome. Indeed, the expression of several molecules involved in T-cell activation and costimulation were found to be elevated in NO ID patients compared with ID and flares (Fig. S7) , confirming that the differential DNA methylation of genes related to T-cell activation observed in NO ID patients is associated with altered expression of the encoded proteins.
Discussion
A long-standing goal in clinical JIA management is the ability to identify patients at high risk of disease relapse following anti-TNF treatment withdrawal to inform clinical decisions, and reduce the associated safety and cost concerns of long-term treatment in low-risk patients. We aimed to uncover the immunological mechanisms underlying the varying clinical responses to treatment withdrawal by studying differential DNA methylation of CD4 + T cells from JIA patients. We observed clear differences in the DNA methylation of immunologically relevant genes-particularly those involved in T-cell activation and TCR signalingin patients with divergent clinical outcomes, which were not associated with age or gender.
There is accumulating evidence that epigenetics plays a role in RA pathogenesis. Differences in DNA methylation patterns of synovial fibroblasts (35) (36) (37) (38) and PBMC/T cells (4, 5, 9) have been observed between RA patients and healthy controls. In JIA, differential methylation of CD4 + T cells has also been reported (6) . However, studies on the association between epigenetics and persistence of clinical remission upon therapy withdrawal in arthritis (adult or juvenile) are limited. To our knowledge, our work is unique in proposing an epigenetic discrimination between clinical activity states. The identification of biomarkers of responsiveness to therapy and off-therapy maintenance of disease remission remains a long-standing unmet clinical need in the rheumatological community (19) . Our work uncovers the potential of DNA methylation to identify changes to the epigenetic regulation of immunologically relevant genes in different disease activity states, and warrants larger association studies aiming at identifying predictive epigenetic biomarkers. In this regard, it is worth noting that the epigenetic features associated with clinical outcome were already visible at the time of therapy withdrawal, demonstrating that methylation changes precedeand thus might predict, or even cause-clinical manifestations. This predictive potential of DNA methylation is in line with the notion that epigenetic mechanisms regulate both the current state of the cell and its predisposition to respond to environmental cues in specified ways (39) . In this context, it is worth mentioning that only minor associations were observed with the time point, suggesting that detectable longitudinal changes upon therapy withdrawal are sparse (but still linked to T-cell regulation).
Our data also point to a functional impact of DNA methylation on disease pathogenesis. Indeed, the CpG modules associated with clinical outcome also correlated with differential protein expression, and may thus actively regulate autoimmune activation. Consistent with this notion, the identified CpG modules were either enriched in genes located in the MHC locus, notoriously enriched in immune-related genes, or were involved in T-cell activation and costimulation. We recently identified a subset of circulating pathogenic-like T cells, which comprise highly activated, HLA-DR-expressing T-cell clonotypes recirculating through the inflamed synovium, that are enriched in the blood of NO ID compared with ID patients (40, 41) . We speculate that the DNA methylation signature of heightened T-cell activation and increased HLA-DR expression in NO ID patients observed here may be driven by this cell subset. Future studies probing the methylome of purified circulating pathogenic-like T cells may be useful to understand their importance in disease pathogenesis and their responsiveness to therapy.
Whereas the DNA methylation signatures of the intermediate NO ID state differed from the other clinical outcomes (seven significantly different CpG modules), the signatures of ID patients and flares overlapped considerably. Given the relative stability of DNA methylation over time, it is conceivable that an acute event, such as a flare, would not allow sufficient time for methylation to be perturbed. Moreover, during flaring episodes, pathogenic cells extravasate rapidly to the peripheral tissues, where they participate in inflammation and damage. Therefore, it may be necessary to examine the epigenetic signature of flare within the inflamed tissue rather than in the circulation. By contrast, immune dysregulation occurring in NO ID patients is subtler and may not lead to the same mass migration of inflammatory cells to the joints, leaving a residual signature within the circulation that we were able to detect.
The association of RNA features with clinical outcome was noticeably weaker than that obtained using DNA methylation features (FDR-adjusted P = 4.63e-2 for gene module #5 vs. 2.29e-4 for CpG module #14). The 2-log difference in sensitivity is striking, especially when considering the different statistical power of the two analyses: although the number of samples tested was very similar between the two platforms (<8% difference), DNA methylation required a much stricter FDR correction because of the higher number of features tested (i.e., 31 vs. 11 modules). Our data indicate that DNA methylation profiling may be a more-sensitive discovery platform than gene-expression profiling. Several reasons might contribute to this differential performance. First, in contrast to RNA expression, which fluctuates rapidly in response to external cues, including both biological stimuli and technical manipulation, DNA methylation is more robust to perturbations (19) . Thus, DNA methylation-based clinical diagnostic assays may be preferable, particularly in the context of multicenter clinical trials where transport and processing are likely to introduce confounding variation.
Second, only a small proportion of circulating cells are actively involved in disease perpetuation; thus, the small signal from these pathogenic cells becomes diluted within the noise generated by all other irrelevant CD4 + T cells. In this respect, DNA methylation is superior to gene-expression profiles in uncovering rare cell contributions from complex samples for at least two reasons: (i) DNA methylation is binary (at each allele, a single CpG dinucleotide is either methylated or not), and even at a population level, its distribution usually remains bimodal (i.e., most CpG sites are either hypomethylated or hypermethylated), whereas RNA expression patterns are complex, varying from cell to cell; (ii) each cell contributes equally to the bulk DNA methylation levels as DNA content is equal in all cells, whereas a few outlier cells with higher transcript abundance dominate bulk geneexpression measurements, skewing the population mean. The combined effect of these two components is that the effect of a rare cell subset on the bulk DNA methylation measurement of the mixed population is linearly proportional to their relative abundance. In contrast, the contribution of the same rare cell subset may be easily masked in gene-expression profiling. Because we expect that only a few circulating cells are contributing to the clinical outcome, most differences could be picked up more efficiently by DNA methylation than by gene expression. Consistently, we were able to identify only a few T-cell activation markers by gene expression, such as HLA-DR/MHC class II and CD86, whose expression in T cells is digital (absent in resting T cells, induced upon stimulation); similar to DNA methylation features, binary expression profiles are easier to detect in population measurements. In contrast, most other activation markers show subtler changes; unlike digital expression, differences in analog expression are hard to detect by bulk measurements. This limitation might be mitigated by single-cell transcriptome analyses or by switching to other single-cell techniques, such as flow cytometry. In line with this notion, flow cytometric analysis of key T-cell activation markers showed strong correlation with the DNA methylation data. Of note, the contribution of rare cell populations in unsegregated samples might be further masked by the common practice of thresholding on arbitrary minimum differences (usually 10% for DNA methylation and twofold change for gene expression). Although this strategy is useful when analyzing homogenous samples (e.g., cell lines), it may be inappropriate for clinical samples, such as those studied here, that are unlikely to reach this threshold as a result of the low prevalence of diseaserelevant cells.
In conclusion, our data demonstrate that the DNA methylome yields both diagnostically and mechanistically relevant information for maintenance vs. loss of inactive disease in JIA, and provide a blueprint for future large-scale validation studies.
Materials and Methods
We used samples form 68 randomly selected patients recruited in the trial "Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA" (ID: NCT00792233) (Dataset S1). Our study was approved by the SanfordBurnham Medical Research Center Institutional Review Board. All patients/ parents signed assent/consent forms for participation in this study. At baseline (T 0 ), patients were in clinical remission on medication: that is, they maintained ID (12) for at least 6 mo under treatment (anti-TNF). Therapy was withdrawn for 8 mo, after which (T end ) patients were stratified by clinical activity in patients maintaining ID or NO ID. Flares (10) were tested at the time of flare (T end ), and therapy was then reintroduced.
Additional experimental procedures, clinical definitions, and analytical strategies are available in the SI Materials and Methods.
